bcx 1812 has been researched along with zanamivir in 17 studies
| Studies (bcx 1812) | Trials (bcx 1812) | Recent Studies (post-2010) (bcx 1812) | Studies (zanamivir) | Trials (zanamivir) | Recent Studies (post-2010) (zanamivir) |
|---|---|---|---|---|---|
| 25 | 1 | 12 | 1,168 | 85 | 546 |
| Protein | Taxonomy | bcx 1812 (IC50) | zanamivir (IC50) |
|---|---|---|---|
| Chain A, Neuraminidase | Influenza B virus (STRAIN B/BEIJING/1/87) | 0.004 | |
| Chain A, Neuraminidase | Influenza B virus (STRAIN B/BEIJING/1/87) | 0.004 | |
| Chain A, Neuraminidase | Influenza A virus | 0.004 | |
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.0054 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.0364 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 0.0027 | |
| Neuraminidase | Influenza A virus (A/Brisbane/59/2007(H1N1)) | 0.0276 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.0017 | |
| Neuraminidase | Influenza A virus (A/Memphis/1/1971(H3N2)) | 0.0147 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.0809 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.0154 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.001 | |
| Neuraminidase | Influenza B virus (STRAIN B/VICTORIA/3/85) | 0.0045 | |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | 0.0077 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0074 | |
| Neuraminidase | Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) | 0.0074 | |
| Neuraminidase | Influenza A virus (A/RI/5+/1957(H2N2)) | 1.4 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.0229 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0007 | |
| Neuraminidase | Influenza B virus (B/Perth/211/2001) | 0.0882 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0024 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.007 | |
| Neuraminidase | Influenza A virus (A/budgerigar/Hokkaido/1/1977(H4N6)) | 0.0228 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0027 | |
| Integrase | Human immunodeficiency virus 1 | 0.0025 | |
| Sialidase-3 | Homo sapiens (human) | 5.6617 | |
| Sialidase-2 | Homo sapiens (human) | 6.7333 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ananth, SL; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Elliott, AJ; Horn, LL; Hutchison, TL; Kotian, P; Laver, GW; Lin, TH; Montgomery, JA; Parker, CD | 1 |
| Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Elliott, AJ; Hutchison, TL; Kotian, PL; Lin, TH; Montgomery, JA | 1 |
| Colman, PM; Fernley, RT; McDonald, M; McKimm-Breshkin, JL; Smith, BJ; Varghese, JN | 1 |
| Chen, XG; Chen, YL; Hu, ZD; Liu, MC; Lü, WJ; Luan, F; Ma, WP; Zhang, XY | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Barr, IG; Holien, JK; Hurt, AC | 1 |
| Demmler-Harrison, GJ; Deyde, VM; Gubareva, LV; Klimov, AI; Okomo-Adhiambo, M; Sheu, TG; Xu, X | 1 |
| Chavas, LM; Dyason, JC; Fusi, P; Kato, R; Mann, MC; McKimm-Breschkin, J; Monti, E; Suzuki, N; Tettamanti, G; Thomson, RJ; Tringali, C; Venerando, B; von Itzstein, M; Wakatsuki, S | 1 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| Barrett, S; McKimm-Breschkin, JL; Newman, J; Oakley, AJ; Peat, TS; Saito, T; Streltsov, VA; Tashiro, M; Waddington, L | 1 |
| Boulanger, MJ; Brant, MG; Bromba, CM; Chan, T; Lunke, MD; Mason, JW; Petric, M; Wulff, JE | 1 |
| Cheng, TJ; Cheng, YS; Fang, JM; Huang, WI; Tsai, KC; Tseng, YC; Wang, PC; Wang, SY; Wong, CH | 1 |
| Cairo, CW; Guo, T; Hunter, CD; Richards, MR | 1 |
| Bi, Y; Cheng, S; Li, C; Li, X; Lv, X; Wang, P | 1 |
| Bourguet, E; Figurska, S; Fra Czek, MM | 1 |
| Aljohani, MA; Keil, JM; Rafn, GR; Sahebjam-Atabaki, R; Sun, XL; Turan, IM | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 review(s) available for bcx 1812 and zanamivir
| Article | Year |
|---|---|
Human Neuraminidases: Structures and Stereoselective Inhibitors.
Topics: Amino Acid Sequence; Enzyme Inhibitors; Humans; Models, Molecular; Neuraminidase; Stereoisomerism; Structure-Activity Relationship | 2022 |
Sialidase Inhibitors with Different Mechanisms.
Topics: Antiviral Agents; Biological Products; Enzyme Inhibitors; Humans; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Sialic Acids; Zanamivir | 2022 |
15 other study(ies) available for bcx 1812 and zanamivir
| Article | Year |
|---|---|
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Topics: Acids, Carbocyclic; Administration, Oral; Animals; Antiviral Agents; Catalytic Domain; Crystallography, X-Ray; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Mice; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Protein Binding; Stereoisomerism; Structure-Activity Relationship | 2000 |
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
Topics: Acids, Carbocyclic; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Cyclopentanes; Enzyme Inhibitors; Guanidines; Influenza A virus; Models, Molecular; Neuraminidase; Protein Binding; Stereoisomerism; Structure-Activity Relationship | 2001 |
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Alphainfluenzavirus; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Pyrans; Sialic Acids; Zanamivir | 2002 |
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Topics: Enzyme Inhibitors; Linear Models; Models, Biological; Neuraminidase; Quantitative Structure-Activity Relationship | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Influenza A Virus, H5N1 Subtype; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Topics: Antiviral Agents; Cells, Cultured; Child, Preschool; Drug Resistance, Viral; Genetic Testing; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Molecular Sequence Data; Neuraminidase; Oseltamivir; Point Mutation; Sequence Analysis, DNA | 2010 |
Complexity in influenza virus targeted drug design: interaction with human sialidases.
Topics: Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Models, Molecular; Molecular Conformation; Neuraminidase; Orthomyxoviridae | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hydrogen Bonding; Influenza B virus; Models, Molecular; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2010 |
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neuraminidase; Protein Binding; Recombinant Proteins; Zanamivir | 2011 |
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Neuraminidase; Rabbits; Structure-Activity Relationship | 2016 |
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
Topics: Amino Acid Sequence; Antiviral Agents; Binding Sites; Catalytic Domain; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Isoenzymes; Kinetics; Molecular Dynamics Simulation; Neuraminidase; Sequence Alignment; Viral Proteins; Zanamivir | 2018 |
Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
Topics: Animals; Antiviral Agents; Cholesterol; Drug Resistance, Viral; Enzyme Inhibitors; Half-Life; Humans; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Rats; Rats, Sprague-Dawley; Virus Replication; Zanamivir | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |